Insulin Therapy in Type 2 Diabetic Subjects Suppresses Plasminogen Activator Inhibitor (PAI‐1) Activity and Proinsulin‐like Molecules Independently of Glycaemic Control

Diabetic Medicine

Volumn 10, Issue 1, 1993, Pages 27-32

  Jain, S K ^a   Nagi, D K ^a   Slavin, B M ^b   Lumb, P J ^b   Yudkin, J S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

32,33 Split proinsulin; C peptide; Lipoproteins Apoproteins; Plasminogen activator inhibitor; Proinsulin

Indexed keywords

C PEPTIDE; INSULIN; LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROINSULIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

APOLIPOPROTEINS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-PEPTIDE; COMPARATIVE STUDY; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMAN; HYPOGLYCEMIC AGENTS; INSULIN; LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; MALE; MIDDLE AGE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROINSULIN; REGRESSION ANALYSIS; SUPPORT, NON-U.S. GOV'T;

EID: 0027537594     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.1993.tb01992.x     Document Type: Article

References (26)

1. UK Prospective Study of therapieso fmaturity‐onsetdiabets: 1. Effect diet, sulphonylrea, insulinor biguanide therapy on fasting plasma glucose and body weight over one year
2. Insulin therapy in obese, non‐insulin‐dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal
3. The effect of insulin treatment on insulin secretion and insuiln action in type II diabetes mellitus
4. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus
5. Insulin therapy induces antiatherogenic chanes of serum liporoteins in non‐insulin‐dependent diabetes
6. The relationships of concentrations of insulin, intact proinsulin and 32, 33 split pronisulin with cardiovascular risk factors in type 2 (non‐insulindependent) diabetic subjects
7. Insulin deficiency in noninsulin‐dependent diabetes
8. Radioimmunoassay may overestimate insulin in non‐insulin‐dependent diabetics
9. A comparison of 3 methods for assessing insulin sensitivity in subjects with normal and abnormal glucose tolerance
10. The reproducibility of the insulin sensitivity test (IST) without pancreatic suppression (modified Haranon technique) as an index of insulin resistane in non‐insulin‐dependent diabetic subjects (Abstract)
11. Sensitive and specific two‐site immunoradiomentric assays for human insuin, proinsulin, 65‐66 split and 32‐33 splitt proinsulin
12. 1 and B using Cobas Bio centrifugal analyser
13. Defective fibrinolysis in non‐insulin‐dependent diabetics relate to plasma insulin concentrations (Abstract)
14. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients
15. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
16. Insulin stimulates the synthesis of plasminogen activator inhibitor‐1 by the human hepetocellular cell line Hep G2
17. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes
18. Stimulation by proinsulin of expression of plasminogen activator inhibitor type‐1 in endothelial cells
19. Effects of biosynthetic human proinsulin on plasma lipids in type 2 diabetes mellitus
20. The long‐term effects of chlorpropamide on insulin, C‐peptide, and proinsulin secretion
21. The effect of exogenous hyperinsulinemia on proinsulin secretion in normal man, obese subjects, and patients with insulinoma
22. Effect of conventional and intensified insulin therapy on freeinsulin profiles and glycemic control in NIDDM
23. Pathways of protein secretion in eukaryotes
24. 1 hyperglycaemia (Abstract)
25. Biosynthetic human proinsulin: review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience